Your browser doesn't support javascript.
loading
Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years.
Ott, Christian; Mahfoud, Felix; Mancia, Giuseppe; Narkiewicz, Krzysztof; Ruilope, Luis M; Fahy, Martin; Schlaich, Markus P; Böhm, Michael; Schmieder, Roland E.
Afiliación
  • Ott C; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Nürnberg, Germany.
  • Mahfoud F; Department of Nephrology and Hypertension, Paracelsus Medical University, Nürnberg, Germany.
  • Mancia G; Klinik für Innere Medizin III, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.
  • Narkiewicz K; Department of Medicine, University of Milano-Bicocca, St. Gerardo Hospital, Monza, Italy.
  • Ruilope LM; Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland.
  • Fahy M; Hypertension Unit, Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain.
  • Schlaich MP; Medtronic, Santa Rosa, CA, USA.
  • Böhm M; School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth, WA, Australia.
  • Schmieder RE; Klinik für Innere Medizin III, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.
Nephrol Dial Transplant ; 37(2): 304-310, 2022 01 25.
Article en En | MEDLINE | ID: mdl-34109413
BACKGROUND: Activity of the sympathetic nervous system is increased in patients with hypertension and chronic kidney disease (CKD). Here we compare short- and long-term blood pressure (BP)-lowering effects of renal denervation (RDN) between hypertensive patients with or without CKD in the Global SYMPLICITY Registry. METHODS: Office and 24-h ambulatory BP (ABP) were assessed at prespecified time points after RDN. The presence of CKD was defined according to the estimated glomerular filtration rate (eGFR) and enrolled patients were stratified based on the presence (n = 475, eGFR <60 mL/min/1.73 m2) or absence (n = 1505, eGFR ≥60mL/min/1.73 m2) of CKD. RESULTS: Patients with CKD were older (P < 0.001) and were prescribed more antihypertensive medications (P < 0.001). eGFR decline per year was not significantly different between groups after the first year. Office and 24-h ABP were significantly reduced from baseline at all time points after RDN in both groups (all P < 0.001). After adjusting for baseline data, patients without CKD had a greater reduction in office systolic BP (-17.3 ± 28.3 versus -11.7 ± 29.9 mmHg; P = 0.009) but not diastolic BP at 36 months compared with those with CKD. Similar BP and eGFR results were found when the analysis was limited to patients with both baseline and 36-month BP data available. There was no difference in the safety profile of the RDN procedure between groups. CONCLUSIONS: After adjusting for baseline data, 24-h systolic and diastolic ABP reduction were similar in patients with and without CKD after RDN, whereas office systolic but not diastolic BP was reduced less in patients with CKD. We conclude that RDN is an effective antihypertensive treatment option in CKD patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Hipertensión Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nephrol Dial Transplant Asunto de la revista: NEFROLOGIA / TRANSPLANTE Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Hipertensión Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nephrol Dial Transplant Asunto de la revista: NEFROLOGIA / TRANSPLANTE Año: 2022 Tipo del documento: Article País de afiliación: Alemania